October 2022 Alzheimer’s News

There is an exciting major development about the potential for a new treatment for Alzheimer’s disease. Clinical trial results were announced for a drug called Lecanamab which was tested in individuals living with mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s dementia. Results from the clinical trial found that this treatment significantly reduces clinical decline from the disease. These results indicate Lecanamab may give people more time at or near their full abilities to participate in daily life, remain independent and make future health care decisions. More information is to be released at the end of November. It’s important to manage our own expectations since this treatment is not yet Food and Drug Administration (FDA) approved and is not yet available in doctor’s offices.
You can learn more by going to www.alz.org/help-support/resources or the Alzheimer’s Helpline which is accessible 24/7 via 800-272-3900 and staffed by master’s level clinicians to assist with crisis situations, decision making, and disease information. You can find virtual dementia caregiver resources online at alz.org/covid19help. Tools and support are also available in Spanish.
Want to learn more about the Alzheimer’s Association and what they do here in St. Louis? Visit alz.org and/or contact PUCC’s Faith Outreach Ambassador with the Alzheimer’s Association, Joyce Ruiz at joyceruiz7@gmail.com